1. Home
  2. FGMC vs CTOR Comparison

FGMC vs CTOR Comparison

Compare FGMC & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGMC
  • CTOR
  • Stock Information
  • Founded
  • FGMC 2023
  • CTOR 2021
  • Country
  • FGMC United States
  • CTOR United States
  • Employees
  • FGMC N/A
  • CTOR N/A
  • Industry
  • FGMC
  • CTOR
  • Sector
  • FGMC
  • CTOR
  • Exchange
  • FGMC NYSE
  • CTOR NYSE
  • Market Cap
  • FGMC 98.9M
  • CTOR 89.9M
  • IPO Year
  • FGMC 2025
  • CTOR N/A
  • Fundamental
  • Price
  • FGMC $9.60
  • CTOR $0.67
  • Analyst Decision
  • FGMC
  • CTOR Strong Buy
  • Analyst Count
  • FGMC 0
  • CTOR 2
  • Target Price
  • FGMC N/A
  • CTOR $4.50
  • AVG Volume (30 Days)
  • FGMC 23.2K
  • CTOR 3.9M
  • Earning Date
  • FGMC 01-01-0001
  • CTOR 05-21-2025
  • Dividend Yield
  • FGMC N/A
  • CTOR N/A
  • EPS Growth
  • FGMC N/A
  • CTOR N/A
  • EPS
  • FGMC N/A
  • CTOR N/A
  • Revenue
  • FGMC N/A
  • CTOR N/A
  • Revenue This Year
  • FGMC N/A
  • CTOR N/A
  • Revenue Next Year
  • FGMC N/A
  • CTOR N/A
  • P/E Ratio
  • FGMC N/A
  • CTOR N/A
  • Revenue Growth
  • FGMC N/A
  • CTOR N/A
  • 52 Week Low
  • FGMC $4.48
  • CTOR $0.55
  • 52 Week High
  • FGMC $9.85
  • CTOR $49.00
  • Technical
  • Relative Strength Index (RSI)
  • FGMC N/A
  • CTOR N/A
  • Support Level
  • FGMC N/A
  • CTOR N/A
  • Resistance Level
  • FGMC N/A
  • CTOR N/A
  • Average True Range (ATR)
  • FGMC 0.00
  • CTOR 0.00
  • MACD
  • FGMC 0.00
  • CTOR 0.00
  • Stochastic Oscillator
  • FGMC 0.00
  • CTOR 0.00

About FGMC FG MERGER II CORP

FG Merger II Corp is a blank check company, incorporated for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (Business Combination).

About CTOR CITIUS ONCOLOGY INC

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Share on Social Networks: